Thursday, May 2, 2024
Home Biotech News 2022 Watch List Page 4

2022 Watch List

    Featured posts

    Revive Therapeutics (RVVTF) Provides Update of Psilocybin Pharmaceutical Programs

    Biotech News Editor / Curator -
    IRB approval to initiate Phase 2 study for methamphetamine abuse disordersAdvancing psilocybin oral thin film, microneedle patch and biosynthesis programs

    Adding Immix Biopharma (IMMX) to 2022 Biotech 12 Pack List.

    Biotech News Editor / Curator -
    Added to 12 Biotech Stocks we Expect to Double List. The Original Biotech 6-Pack from 2020, is Growing to...

    The Race to Develop Therapeutics for COVID. The Small Caps Fight for a Treatment...

    2022 Watch List Editor / Curator -
    The Second Wave: Biopharma Players Race to Develop Therapeutics for COVID-19 (BioSPace) December 21. Revive Therapeutics (RVTTF), RedHill BioPharma...

    Revive Therapeutics (RVVTF, RVV.CN) in Discussions to Secure Supply of 5 Billion Bucillamine Tablets.

    2022 Watch List Editor / Curator -
    Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 Not wanting to be caught...
    1234Page 4 of 4

    Latest article

    Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.

    2024 Watch List Editor / Curator -
    Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!

    Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.

    2024 Watch List Editor / Curator -
    CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization...

    GeoVax (GOVX) Launches Vaccine Manufacturing System.

    2024 Watch List Editor / Curator -
    GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System Manufacturing Process for Phase 3 and Commercial Production...
    The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
    Contact us: [email protected]
    © Managed by Revelers.IO Media Group Inc.